RT Journal
A1 Kaul S, Morrissey RP, Diamond GA
T1 BY jove! what is a clinician to make of jupiter?
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2010
FD June 28
VO 170
IS 12
SP 1073
OP 1077
DO 10.1001/archinternmed.2010.189
UL http://dx.doi.org/10.1001/archinternmed.2010.189
AB 
On February 9, 2010, the US Food and Drug Administration (FDA) extended its approval of rosuvastatin to include the indication for reducing the risk of stroke, myocardial infarction (MI), and revascularization procedures in individuals who have normal low-density lipoprotein cholesterol (LDL-C) levels and no clinically evident coronary heart disease but have an increased risk based on age, high-sensitivity C-reactive protein (hsCRP) levels, and the presence of at least 1 additional cardiovascular disease risk factor.1 The decision by the FDA was based on results from the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study, which demonstrated a 44% risk reduction in the primary end point in 17 802 primary prevention patients randomly allocated to treatment with rosuvastatin, 20 mg, compared with placebo.2